Navigation Links
Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD
Date:9/10/2008

Non-stimulant drug addresses wide range of symptoms of ADHD

DURHAM, N.C., Sept. 10 /PRNewswire/ -- A drug that diminishes the body's hyper-reactivity to stress has been shown to significantly reduce symptoms of attention-deficit hyperactivity disorder (ADHD) in children, according to a phase 3 clinical trial conducted by Addrenex Pharmaceuticals.

The study showed that the new drug, Clonicel, achieved statistically significant improvement over placebo in reducing an aggregate of 18 ADHD symptoms listed by the American Psychiatric Association and used by physicians to diagnose and classify the condition.

"This is the first study to validate the potential for a long-acting version of clonidine -- a widely used hypertension drug -- as a safe and effective treatment for ADHD," said Moise Khayrallah, Ph.D., CEO of Addrenex Pharmaceuticals, a small Durham start-up that initiated and coordinated the multicenter trial.

Previous studies of clonidine have indicated that the drug diminishes select symptoms of ADHD, but these studies have been small and inconclusive, Khayrallah said. Moreover, clonidine carries bothersome side effects that have limited its use, including a peak of drowsiness when the drug is absorbed and a subsequent rebound of symptoms when drug levels subside.

Addrenex scientists developed Clonicel to reduce these side effects and treat specific ADHD symptoms that may occur when the body's adrenergic system is in overdrive, producing excessive levels of the stress hormone adrenaline. Such symptoms include emotional outbursts, mood swings, insomnia and hyperreactivity to stress.

"We conducted a well-powered, randomized clinical trial to demonstrate that Clonicel may be effective on its own in treating a multitude of ADHD symptoms, with a favorable side effect profile," said Khayrallah. "We're very excited with the positive data we obtained, and we intend for this study to serve as part of the basis for review
'/>"/>

SOURCE Addrenex
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
2. Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351
3. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
4. Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials
5. Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
6. Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies
7. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
8. Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
9. Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy
10. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
11. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)...   Health 2.0 announces Bernard Tyson , ... Eric Topol , Patrick Soon-Shiong , and Samsung,s ... 8th Annual Fall Conference this coming Sept. 21-24 in ... 2.0 is set to host the very first Wearable Tech ... Consumer Tech & Wearables: Powering Healthy Lifestyles. The ...
(Date:7/28/2014)... July 28, 2014 Anthera Pharmaceuticals, Inc. (NASDAQ: ... for the second quarter ended June 30, 2014. ... 2014 was $7.3 million, compared to $8.3 million for the ... a direct result of a decrease in interest expense in ... six months ended June 30, 2014 was $15.2 million, compared ...
(Date:7/28/2014)... SHORT HILLS, N.J. , July 28, 2014 ... announced a $520,000 settlement of off-label marketing and ... Justice ("DOJ") and Vascular Solutions, Inc. ("VSI").  The ... of various medical devices for endovenous laser ablation ... Stone & Magnanini, a firm with a history ...
Breaking Medicine Technology:Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 2Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 3Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 2Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 3Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 4Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 5Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 6Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 7Stone & Magnanini LLP Announces $520,000 Department of Justice False Claims Act Settlement With Vascular Solutions, Inc. 2Stone & Magnanini LLP Announces $520,000 Department of Justice False Claims Act Settlement With Vascular Solutions, Inc. 3
... initiate Phase 1 trial of AKIi-5 as the first ... ... Aug. 2 Quark Pharmaceuticals, Inc., a,clinical-stage biopharmaceutical company ... today the,presentation of positive results from preclinical efficacy studies ...
... PHILADELPHIA, Aug. 3 GlaxoSmithKline (NYSE:,GSK), one of ... has placed another order to purchase bulk H5N1 ... The company also announced the,start of the first ... pre-pandemic influenza program. HHS Order The ...
Cached Medicine Technology:Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF) 2Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF) 3Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF) 4GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSK's Candidate Pre-pandemic Flu Vaccine to Start. 2GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSK's Candidate Pre-pandemic Flu Vaccine to Start. 3GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSK's Candidate Pre-pandemic Flu Vaccine to Start. 4
(Date:7/29/2014)... 29, 2014 PeopleKeys today announced that ... teach students how to train and certify others in ... Behavioral Consultant Trainer , will be taught by PeopleKeys ... Training John Schindell as a live Tele-course over the ... The Certified Behavioral Consultant Trainer course will use a ...
(Date:7/29/2014)... In today’s world, a good night’s sleep has ... sleep apnea (a medical problem where the airway collapses during ... of the rest they need to face their daily challenges. ... 20 million people in the United States alone have sleep ... and of those treated, many cannot tolerate their prescribed medical ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 In its ... offers treatment programs and believes that having family close ... big difference in whether or not the process is ... myths. , “It’s difficult to estimate just how damaging ... Rehabilitation’s CEO Per Wickstrom . “Not only do ...
(Date:7/29/2014)... 2014 Nuanced Media, a leading digital ... HIPAA (Health Insurance Portability and Accountability Act) certified firm. ... storage and transfer of Personal Health Information (PHI). ... Nuanced Media can effectively serve their medical industry clients. ... to offer medical industry specific products such as ...
(Date:7/29/2014)... brides want their bridal dresses and bridal parties to ... sure to provide designs of wedding gowns and bridesmaids ... has recently announced its new collection of gorgeous lace ... come with big savings, up to 61% off. , ... working in the garment industry for several years; they ...
Breaking Medicine News(10 mins):Health News:PeopleKeys Announces New Certified Behavioral Consultant Trainer Course 2Health News:PeopleKeys Announces New Certified Behavioral Consultant Trainer Course 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Latest Best Drug Rehabilitation Blog Post Busts 4 Big Addiction Myths 2Health News:Latest Best Drug Rehabilitation Blog Post Busts 4 Big Addiction Myths 3Health News:Nuanced Media Web Design Agency Now Hipaa Certified 2Health News:LunaDress’ Summer Sale Has Arrived: All Its Gorgeous Lace Wedding Dresses are Affordable Now 2
... Epidemiologists have long warned that, in addition to causing ... person at greater risk for colon cancer. Now, researchers ... explain why. The findings, "Epigenetic Differences in Normal ... Pathways," were published in the March issue of the ...
... HIV-positive patient, one of her first questions is whether he ... response is about dead relatives or friends. "We talk about ... experience will be very different," said the infectious-disease specialist at ... "Yes it,s the same virus and could have the same ...
... Researchers from Boston University School of Medicine (BUSM) and ... breast pain who receive imaging (mammograms, MRIs or ultrasounds) ... testing, but do not gain benefit from these additional ... of General Internal Medicine. Breast pain is ...
... -- Exposure to cocaine, tobacco or marijuana before birth ... tests, according to a new study. Prenatal alcohol ... fetal alcohol syndrome, was associated with lower scores at ... researchers found. The negative associations between intrauterine alcohol ...
... Reporter , TUESDAY, March 6 (HealthDay News) -- New research ... longevity in humans by showing that genetically modified mice live ... a few differences between mice and humans, especially in regard ... genetic tweak, so there,s no way to know if the ...
... -- When faced with stressful situations, older adults who sleep ... a new study finds. The marker, called interleukin-6 (IL-6), ... as cardiovascular disease, diabetes and psychiatric problems. "Our study ... sleep and what poor sleep may be doing to our ...
Cached Medicine News:Health News:Study shows how high-fat diets increase colon cancer risk 2Health News:Federal grant enables HIV testing, treatment in the Augusta area 2Health News:Federal grant enables HIV testing, treatment in the Augusta area 3Health News:Research finds little benefit of breast imaging tests for women with breast pain 2Health News:Fetal Cocaine Exposure May Not Affect Kids' Academics: Study 2Health News:Genetic Tweak Helps Mice Avoid Cancer, Obesity: Study 2Health News:Poor Sleep May Impact Stress Response in Older Adults 2
... is an excellent choice to treat DeQuervain's ... joint, basal joint arthritis, advanced carpal tunnel ... thumb and wrist. Distal palmar crease ... and full finger dexterity. Constructed from ...
... Wrist Flex is a custom wrist orthotic designed to ... to the patient's maximum range-of-motion. , ,Indications: , ... TFCC tear-triangular fibrocartilage complex , Coles fracture ... , Partial tendon rupture , ORIF ...
The Contoured Wrist/Forearm Support provides comfort for post-surgical immobilization, post-fracture casting, and wrist sprains and strains....
Design allows for easy-one hand application to provide support and immobilization of the wrist while preserving finger mobility...
Medicine Products: